Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus Chemotherapy in 1st-Line Advanced Urothelial Carcinoma
NCT04568304Phase 3Withdrawn
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in urothelial carcinoma (UC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Planned start Sep 2022; status: withdrawn.
02
Drugs
toripalimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04568304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568304.